Molecular Partners AG (MLLCF) Research

Molecular Partners AG operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of therapeutic protein treatments. Its portfolio of investigational products, primarily based on DARPin technology, features Abicipar, which is undergoing Phase III clinical trials for the management of neovascular wet age-related macular degeneration and diabetic macular edema. Another significant candidate is MP0420, a multi-specific DARPin designed to combat the SARS-CoV-2 virus. The company's pipeline further includes MP0310, in Phase Ia for immuno-oncology applications; MP0317, a tumor-localized immune agonist that stimulates immune cells within tumors, currently in Phase I; and MP0274, also in Phase I for HER2-positive cancers. Additional developments include MP0423 for treating COVID-19; MP0533, a CD3 T cell-targeting agent for acute myeloid leukemia; and MP0250, engineered to interact with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to prolong its half-life. Molecular Partners AG maintains collaborations with major pharmaceutical companies such as Novartis AG (for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies), Amgen SA, and Allergan, Inc., alongside a discovery alliance in ophthalmology with AbbVie Inc., and other third-party partners. The company, established in 2004, is headquartered in Schlieren, Switzerland.

Open Molecular Partners AG (MLLCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.